



Premature Aging among Survivors of Childhood Cancer

POGO After Care Education Day
2024

AnnaLynn Williams, PhD

Assistant Professor

Department of Surgery

Division of Supportive Care in Cancer

University of Rochester Medical Center

James P. Wilmot Cancer Institute





UR
MEDICINE

WILMOT
CANCER INSTITUTE

Childhood Cancer in the U.S. & Canada


5-year Relative Survival of Childhood Cancer Patients



<https://health-infobase.canada.ca/data-tools/cypc/>
www.pogo.ca


Excess Mortality

- U.S. SEER-9 registries, diagnosed age 0 to <20, between 1975 and 2016
- **Excess Deaths** = Observed - Expected



Williams et al, *J Clin Oncol*, 2021

Excess Morbidity




By Age 50:

- 96% with a Grade 3+ CHC
- Avg 4.7 Grade 3+ CHC


Bhakta et al, Lancet 2017

Accelerated or Premature Aging?



How can we measure aging?

Biologic



- Epigenetic Age
- Telomere Length
- Inflammation

Physiologic



- Fried's Frailty
- Deficit Accumulation
- Chronic Health Conditions

Cognitive



- Objective Neuropsychological Assessment
- Self-Reported Measures

St. Jude Lifetime Cohort


- Established in 2007
- Retrospective/Prospective Cohort
- Eligibility:
 - Treated at St. Jude
 - ≥ 5 years from diagnosis
- Detailed Treatment Data, Wide Range of Clinically Assessed Outcomes
- Non-Cancer Controls

5,000 Survivors of Pediatric Cancer



Howell et al, Clinical Cancer Research 2024

DNA Methylation




”Code” that allows for a change in phenotype without a change in genotype

DNA Methylation



SJLIFE: 2,139 Survivors 282 Controls

- **Peripheral Blood Mononuclear Cell DNA**
- **Illumina EPIC MicroArray Bead Chip: 850K CpG sites**



Epigenetic Age Acceleration (EAA)




Epigenetic Clocks



DNAmPhenoAge
by Levine
513 CpGs

Predicts: Phenotypic Age,
Mortality



Epigenetic Age Acceleration (EAA)




Epigenetic Clocks




DNAmPhenoAge
by Levine
513 CpGs

**Predicts: Phenotypic Age,
Mortality**



Epigenetic Age Acceleration (EAA)





Survivors have significantly greater epigenetic age acceleration

Qin et al, JNCI 2020



Epigenetic Age Acceleration




Qin et al, JNCI 2020



Epigenetic Age Acceleration





Mean Epigenetic Age Acceleration (years)



Qin et al, JNCI 2020

Epigenetic Age Acceleration



Qin et al, JNCI 2020


EAA and Chronic Health Conditions



EAA Assoc with:

- Hypertension
- MI
- Obesity
- Pulmonary disease
- Sleep apnea
- Neuropathy

Health Behaviors



Qin et al, JNCI 2020



Fried's Frailty



Physiologic Frailty



Weakness

↓ grip strength

Unintentional Weight Loss

>4.5kg in 12 months

Low Physical Activity

↓energy expenditure (kcal/wk)

Slowness

↓walking speed

Fatigue

overall feeling of tiredness

3+ Frail


2 Pre-Frail

<2 Robust

Fried et al, J Geront A Biol Sci Med Sci 2001
Ness et al, J Clin Onc 2013



Fried's Frailty




1,922 Survivors
Mean Age 34

341 Controls
Mean Age 29

Ness et al, J Clin Onc 2013 & 2018


Fried's Frailty



Frailty → Mortality
HR 2.6 95%CI (1.2, 6.2)

Ness et al, J Clin Onc 2013 & 2018


Fried's Frailty



Frailty → Mortality
HR 2.6 95%CI (1.2, 6.2)

Ness et al, J Clin Onc 2013 & 2018

Fried's Frailty: Progression



1,432 Survivors
5 years of Follow Up
Median Age: 30 years

9.8% new onset Frailty
15.1% new onset Pre-Frailty

Delaney et al J Natl Cancer Inst 2021

Deficit Accumulation Index



Conceptualizes aging as a process of an accumulation of deficits

Deficit Accumulation Index (DAI)

- accumulation of multiple aging-related deficits
- At least 30-40 aging-related items
- predict mortality in adult cancer patients

SJLIFE DAI: 44 Aging-related Items

For each item:

- 1=deficit present/severe
- 0=deficit absent

$$\text{DAI} = \frac{\text{Sum of items}}{\text{Total number of items}}$$

DAI ranges from 0 to 1

Large clinically meaningful difference: 0.06

Low <0.2 Medium: 0.2-<0.35 High: >=0.35


DAI Construct	Value/Criteria	DAI Item Score
1. Can take bath/shower (IADL)	Yes limited a lot	1
	Yes, limited a little	0.5
	No Not limited at all	0
21. Heart Disease Comorbidity:	≥ 1 Grade 3 /4 Condition	1
	≥ 1 Grade 2 Condition (no grade 3/4)	0.5
	None or Only Grade 1 Conditions	0
39. Hearing Problems	Any "yes, and the condition is still present"	1
	No or Yes, but the condition is no longer present	0

Williams et al, JNCI 2023
Williams et al, JAMA Network Open 2024

Deficit Accumulation Index



Clinically Meaningful Higher DAI in Survivors



4,000 Survivors
683 Controls

Mean Age: 29
Mean Time Since Dx: 20 years



Linear regression models adjusted for age, sex, and race/ethnicity.

Williams et al, JNCI 2023
Williams et al, JAMA Network Open 2024

Deficit Accumulation Index



Clinically Meaningful Higher DAI in Survivors




Linear regression models adjusted for age, sex, and race/ethnicity.

Williams et al, JNCI 2023
Williams et al, JAMA Network Open 2024


Deficit Accumulation Index



Diagnosis




Treatments



Williams et al, JNCI 2023
Williams et al, JAMA Network Open 2024

Deficit Accumulation Index



**Higher DAI Associated
with Increased Risk of
Mortality**

Cox proportional hazards models adjusted for age, sex, race/ethnicity, and year of diagnosis.

Williams et al, JNCI 2023
Williams et al, JAMA Network Open 2024

Cognitive Aging



**Long-Term Survivors
Impaired \geq 3 Tests**

CNS Directed Therapy

- **Cranial Radiation**
- **Neurosurgery**
- **Intrathecal Chemotherapy**

} **49%**

**Survivors with no CNS Directed Therapy
are at risk too!**

} **40%**

Williams et al, Annals of Neurology 2020




Cognitive Aging



Childhood Cancer Survivor Study

- Funded in 1994 (U24 CA55727)
- Retrospective Cohort, recent expansion, include survivors diagnosed 1970-1999
- 31 Contributing Centers
- 5-Year Survival
- Leukemia, Lymphoma, CNS, Bone, Wilms, NBL, Soft-tissue sarcoma
- Detailed Treatment Data, Wide Range of Outcomes



ccss.stjude.org



Cognitive Aging



Sample:

CNS tumors (n=488)

ALL (n=1316)

Hodgkin Lymphoma (n=571)


Siblings (n=232)

Self-Reported Cognitive Function

Approx. 10 years of Follow Up

Excluded Impaired at Baseline

Risk of New Onset Impairment



Phillips et al, JAMA Netw Open 2023

Cognitive Aging



Sample:

CNS tumors (n=488)

ALL (n=1316)

Hodgkin Lymphoma (n=571)


Siblings (n=232)

Self-Reported Cognitive Function

Approx. 10 years of Follow Up


Excluded Impaired at Baseline

Risk of New Onset Impairment




Phillips et al, JAMA Netw Open 2023

Overlap in Aging Pathways




Biologic and Physiologic Aging



**Epigenetic Age Acceleration
Increases
With Deficit Accumulation Index**


Williams et al, JNCI 2023
Williams et al, JAMA Network Open 2024

Physiologic and Cognitive Aging



Williams et al, JNCI 2023
Williams et al, JAMA Network Open 2024

Physiologic and Cognitive Aging




Williams et al, J Clin Onc 2021

Biologic and Cognitive Aging



Non-CNS-Treated Survivors




Williams et al, Under Review
Do not Use without Permission

Biologic and Cognitive Aging



CNS-Treated Survivors



Williams et al, Under Review
Do not Use without Permission

Summary

- Survivors experience premature aging
 - Biologic
 - Physiologic
 - Cognitive
- Biologic, physiologic and cognitive are all connected

Questions Remain

- **Is it truly accelerated aging? Or just premature?**
 - Need for Longitudinal Data
- **When does the aging trajectory start?**
 - Need for pre- post-treatment data
- **How can we target multiple pathways at once?**
 - Need for multidimensional interventions

Clinical Impact

- **Advocate for survivors**
- **Need screening and management for aging related diseases earlier than their peers**
 - **Earlier than their primary care doctors are used to**
- **May need earlier monitoring for aging-related cognitive changes**

Acknowledgments

University of Rochester Medical Center

Nikesha Gilmore, PhD
Michelle Janelsins, PhD
Melissa Loh, PhD, MD
Umang Gada, MS

St. Jude Children's Research Hospital

Kevin Krull, PhD
Leslie Robison, PhD
Kiri Ness, PhD
Melissa Hudson, MD
Nicholas Phillips, MD PhD
Gregory Armstrong, PhD
Yutaka Yasui, PhD
Deokumar Srivastava, PhD
Mingjuan Wang, MS

AYA-Can Lab

Karolina Breit, MS
Elizabeth Diaz Fontanez, MS
Tianming Zhao
Leanna Birsner
Isabelle Ostergaard

Funding

F99K00CA222742 (AMW)
K99R00CA256356 (AMW)
U01CA195547 (MMH/KKN)
P30CA21765 (Roberts),
ALSAC

Patients and Families in SJLIFE and CCSS



Questions?

AnnaLynn Williams, PhD

AnnaLynn_Williams@urmc.Rochester.edu




@AnnaLynnWilliams




Title

- Line 1
- Line 2
- Line 3




Differing Epigenetic Clocks





Williams et al, Under Review

Mean EAA: Differing Epigenetic Clocks



Cognitive Aging



Risk Factors for New Onset Impairment:

ALL w/No CRT:

Female Sex, MTX IT, and Cytarabine → Memory
Alkylators → Task Efficiency

CNS Tumors

Craniospinal RT, Focal RT → Memory

Hodgkin Lymphoma:

Female Sex → Memory
Alkylators → Task Efficiency



Cognitive Aging

